Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma

Oncogene. 2005 Nov 24;24(53):7850-8. doi: 10.1038/sj.onc.1208912.

Abstract

Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a key mediator of angiogenesis for both physiological and pathological conditions. It is well established that the hypoxic induction of VPF/VEGF is in large part an increase in the stability of its mRNA. A Hu family ubiquitously expressed RNA-binding protein HuR has recently been shown to be important for VPF/VEGF mRNA stabilization. In renal cancer cells, the inactivation of the tumor suppressor protein von Hippel Lindau (VHL) leads to an increase in VPF/VEGF expression. VHL not only inhibits the transcription of VPF/VEGF but also plays a significant role in decreasing its mRNA stability. Here we delineate a possible mechanism by which VHL can control the function of HuR in order to regulate the stability of VPF/VEGF mRNA. The experiments presented here suggest that the association of the elongin-binding domain of VHL with a specific RNA-binding domain of HuR (RRM1) is important for the destabilizing function of VHL on VPF/VEGF mRNA.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Renal Cell / genetics*
  • Carcinoma, Renal Cell / physiopathology
  • Elongin
  • Humans
  • Kidney Neoplasms / genetics*
  • Kidney Neoplasms / physiopathology
  • Neovascularization, Pathologic
  • RNA Stability
  • Transcription Factors / metabolism*
  • Tumor Cells, Cultured
  • Vascular Endothelial Growth Factors / biosynthesis*
  • Von Hippel-Lindau Tumor Suppressor Protein / physiology*

Substances

  • Elongin
  • Transcription Factors
  • Vascular Endothelial Growth Factors
  • Von Hippel-Lindau Tumor Suppressor Protein